Kidney Replacement Therapies and Ultrafiltration in Cardiorenal Syndrome [0.03%]
心脏肾病综合征的肾脏替代治疗及超滤疗法
Luz Yareli Villegas-Gutiérrez,Julio Núñez,Kianoush Kashani et al.
Luz Yareli Villegas-Gutiérrez et al.
Background: Some patients with cardiorenal syndrome 1 and congestion exhibit resistance to diuretics. This scenario complicates management and is associated with a worse prognosis. In some cases, rescue treatment may be c...
Exploring the Mechanism of Cardiorenal Protection with Finerenone Based on Network Pharmacology [0.03%]
基于网络药理学的非那伦酮心肾保护机制探究
Yachen Si,Ying Zhu,Jing Liu et al.
Yachen Si et al.
Introduction: Large prospective trials have demonstrated that finerenone could reduce the risk of cardiovascular death and progression of renal failure among patients with chronic kidney disease associated heart failure a...
Publication Trends and Research Hotspots of the Cardiorenal Syndrome: A Bibliometrics and Visual Analysis from 2003 to 2023 [0.03%]
2003-2023年 cardiorenal syndrome 的文献计量和可视化分析：发文趋势与研究热点
Yibo Shi,Zean Fu,Shixiong Wu et al.
Yibo Shi et al.
Introduction: Cardiorenal syndrome encompasses a range of disorders involving both the heart and kidneys, wherein dysfunction in one organ may induce dysfunction in the other, either acutely or chronically. ...
Long-Term Clinical Outcomes of Acute Kidney Disease in Patients Receiving Extracorporeal Membrane Oxygenation [0.03%]
体外膜氧合患者急性肾病的长期临床预后
Ming-Jen Chan,Shao-Wei Chen,Pei-Chun Fan et al.
Ming-Jen Chan et al.
Introduction: Extracorporeal membrane oxygenation (ECMO) is widely used; however, studies on the long-term outcomes of ECMO are scarce. We investigated the long-term clinical outcomes of acute kidney disease (AKD) in pati...
Multicenter Study
Cardiorenal medicine. 2024;14(1):294-306. DOI:10.1159/000539151 2024
Cardiorenal Impact of Anti-Cancer Agents: The Intersection of Onco-Nephrology and Cardio-Oncology [0.03%]
抗癌剂的 cardio-renal 影响：Onco-nephrology 与 cardio-oncology 的交叉点
Rose Mary Attieh,Belen Nunez,Robert S Copeland-Halperin et al.
Rose Mary Attieh et al.
Background: The evolving landscape of cancer treatments has introduced new challenges, particularly related to adverse events associated with chemotherapeutic agents. To address these challenges, the fields of cardio-onco...
Urinary Cell Cycle Arrest Biomarkers and Diuretic Efficiency in Acute Heart Failure [0.03%]
急性心力衰竭患者尿细胞周期阻滞标志物与利尿剂抵抗的关系研究
Gonzalo Núñez-Marín,Gregorio Romero-González,Jordi Bover et al.
Gonzalo Núñez-Marín et al.
Introduction: This study aimed to evaluate the association between the NephroCheck® test AKIRisk® score, diuretic efficiency (DE), and the odds of worsening kidney function (WKF) within the first 72 h of admission in pa...
Tissue Inhibitor Metalloproteinase-2·IGF-Binding Protein 7 for the Prediction of Acute Kidney Injury following Cardiac Surgery [0.03%]
心脏手术后组织型基质金属蛋白酶-2和胰岛素样生长因子结合蛋白7用于预测急性肾损伤
Yun Xie,Qin Guo,Bo Yang et al.
Yun Xie et al.
Introduction: Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common complication associated with increased morbidity and mortality. Tissue inhibitor metalloproteinase-2·insulin-like growth factor-binding p...
Jef Van den Eynde,Frederik H Verbrugge
Jef Van den Eynde
Background: Increased renal sodium avidity is a hallmark feature of the heart failure syndrome. Summary: Increased renal sodium avidity...
Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease [0.03%]
芬戈利尤单抗的心肾获益：不同种族和慢性肾脏病患者肾功能的影响
Pingjiang Li,Yuying Cui,Xiaoming Xu et al.
Pingjiang Li et al.
Background: The mineralocorticoid receptor plays an important pathophysiological role in cardiorenal diseases by causing inflammation and fibrosis. Mineralocorticoid receptor antagonists (MRAs) are well known in treating ...
Treatment of Chronic Heart Failure in Advanced Chronic Kidney Disease: The HAKA Multicenter Retrospective Real-World Study [0.03%]
慢性肾脏病晚期慢性心力衰竭的治疗：HAKA多中心回顾性真实世界研究
Borja Quiroga,Alberto Ortiz,Sara Núñez et al.
Borja Quiroga et al.
Introduction: Chronic heart failure (HF) has high rates of mortality and hospitalization in patients with advanced chronic kidney disease (aCKD). However, randomized clinical trials have systematically excluded aCKD popul...
Multicenter Study
Cardiorenal medicine. 2024;14(1):202-214. DOI:10.1159/000538030 2024